Pippa Mann partners with Genetic Technologies for 2016
Pippa Mann has established another key partnership ahead of her Verizon IndyCar Series program in 2016, announcing a deal with Genetic Technologies on Monday morning.
The full release is below:
Verizon IndyCar Series driver Pippa Mann will partner with Genetic Technologies Limited (NASDAQ: GENE), a molecular diagnostics company specializing in women’s health, in 2016 to promote BREVAGenplus®, the company’s first-in-class, clinically validated risk assessment test for non-hereditary breast cancer.
This new relationship between Pippa and Genetic Technologies further affirms Pippa’s commitment to breast cancer prevention and its associated technologies. Pippa is entering her third year of a partnership with Susan G. Komen®, the world’s largest breast cancer organization.
Driving the pink and white Susan G. Komen car in the past two Indianapolis 500 races, Pippa has raised awareness and funding to support the cause through her IndyCar activities. Pippa is an ambassador for women’s health with several organizations and is active both nationally and locally in her support of Komen.
“I am thrilled to be able to represent another group that is committed to helping end breast cancer by partnering with Genetic Technologies,” said Pippa. “It is fantastic to be able to represent such a game-changing product in the women’s health space. I am looking forward to helping raise the profile of BREVAGenplus® through the exposure that comes with IndyCar and the Indianapolis 500.”
The associate sponsorship agreement between Pippa and Genetic Technologies will consist of apparel representation, participation at BREVAGenplus® oriented events and speaking engagements, social media, print and video campaigns, and related sales support activities. Pippa plans to use this new partnership in the 100th running of the Indianapolis 500 on May 29, 2016.